Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion


Genome-wide association studies have shown that variation in MTNR1B (melatonin receptor 1B) is associated with insulin and glucose concentrations. Here we show that the risk genotype of this SNP predicts future type 2 diabetes (T2D) in two large prospective studies. Specifically, the risk genotype was associated with impairment of early insulin response to both oral and intravenous glucose and with faster deterioration of insulin secretion over time. We also show that the MTNR1B mRNA is expressed in human islets, and immunocytochemistry confirms that it is primarily localized in β cells in islets. Nondiabetic individuals carrying the risk allele and individuals with T2D showed increased expression of the receptor in islets. Insulin release from clonal β cells in response to glucose was inhibited in the presence of melatonin. These data suggest that the circulating hormone melatonin, which is predominantly released from the pineal gland in the brain, is involved in the pathogenesis of T2D. Given the increased expression of MTNR1B in individuals at risk of T2D, the pathogenic effects are likely exerted via a direct inhibitory effect on β cells. In view of these results, blocking the melatonin ligand-receptor system could be a therapeutic avenue in T2D.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Insulin secretion according to different MTNR1B rs10830963 genotypes.
Figure 2: Colocalization of MTNR1B and insulin protein in mouse, rat and human pancreatic islets.
Figure 3: Expression of MTNR1B in human pancreatic islets.

Similar content being viewed by others


  1. Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, & Novartis Institutes of BioMedical Research, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316, 1331–1336 (2007).

  2. Scott, L.J. et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316, 1341–1345 (2007).

    Article  CAS  Google Scholar 

  3. Sladek, R. et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445, 881–885 (2007).

    Article  CAS  Google Scholar 

  4. Zeggini, E. et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat. Genet. 40, 638–645 (2008).

    Article  CAS  Google Scholar 

  5. Zeggini, E. et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 316, 1336–1341 (2007).

    Article  CAS  Google Scholar 

  6. Prokopenko, I. et al. Variants in MTNR1B influence fasting glucose levels and risk of type 2 diabetes. Nat. Genet. advance online publication, doi:10.1038/ng.290 (7 December 2008).

  7. Peschke, E. Melatonin, endocrine pancreas and diabetes. J. Pineal Res. 44, 26–40 (2008).

    CAS  PubMed  Google Scholar 

  8. Kvetnoy, I.M. Extrapineal melatonin: location and role within diffuse neuroendocrine system. Histochem. J. 31, 1–12 (1999).

    Article  CAS  Google Scholar 

  9. Boden, G., Ruiz, J., Urbain, J.L. & Chen, X. Evidence for a circadian rhythm of insulin secretion. Am. J. Physiol. 271, E246–E252 (1996).

    CAS  PubMed  Google Scholar 

  10. Pandi-Perumal, S.R. et al. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog. Neurobiol. 85, 335–353 (2008).

    Article  CAS  Google Scholar 

  11. Muhlbauer, E. & Peschke, E. Evidence for the expression of both the MT1- and in addition, the MT2-melatonin receptor, in the rat pancreas, islet and beta-cell. J. Pineal Res. 42, 105–106 (2007).

    Article  CAS  Google Scholar 

  12. Ramracheya, R.D. et al. Function and expression of melatonin receptors on human pancreatic islets. J. Pineal Res. 44, 273–279 (2008).

    Article  CAS  Google Scholar 

  13. Valle, T. et al. Mapping genes for NIDDM. Design of the Finland-United States Investigation of NIDDM Genetics (FUSION) Study. Diabetes Care 21, 949–958 (1998).

    Article  CAS  Google Scholar 

  14. Eriksson, J.G., Osmond, C., Kajantie, E., Forsen, T.J. & Barker, D.J. Patterns of growth among children who later develop type 2 diabetes or its risk factors. Diabetologia 49, 2853–2858 (2006).

    Article  CAS  Google Scholar 

  15. Marselli, L. et al. Gene expression of purified beta-cell tissue obtained from human pancreas with laser capture microdissection. J. Clin. Endocrinol. Metab. 93, 1046–1053 (2008).

    Article  CAS  Google Scholar 

  16. Peschke, E., Bach, A.G. & Muhlbauer, E. Parallel signaling pathways of melatonin in the pancreatic beta-cell. J. Pineal Res. 40, 184–191 (2006).

    Article  CAS  Google Scholar 

  17. Peschke, E. et al. Melatonin and type 2 diabetes - a possible link? J. Pineal Res. 42, 350–358 (2007).

    Article  CAS  Google Scholar 

  18. Berglund, G. et al. Long-term outcome of the Malmo preventive project: mortality and cardiovascular morbidity. J. Intern. Med. 247, 19–29 (2000).

    Article  CAS  Google Scholar 

  19. Lyssenko, V. et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N. Engl. J. Med. 359, 2220–2232 (2008).

    Article  CAS  Google Scholar 

  20. Lyssenko, V. et al. Genetic prediction of future type 2 diabetes. PLoS Med. 2, e345 (2005).

    Article  Google Scholar 

  21. Lyssenko, V. et al. Predictors of and longitudinal changes in insulin sensitivity & secretion preceding onset of type 2 diabetes. Diabetes 54, 166–174 (2005).

    Article  CAS  Google Scholar 

  22. Steil, G.M., Volund, A., Kahn, S.E. & Bergman, R.N. Reduced sample number for calculation of insulin sensitivity and glucose effectiveness from the minimal model. Suitability for use in population studies. Diabetes 42, 250–256 (1993).

    Article  CAS  Google Scholar 

  23. Yang, Y.J., Youn, J.H. & Bergman, R.N. Modified protocols improve insulin sensitivity estimation using the minimal model. Am. J. Physiol. 253, E595–E602 (1987).

    CAS  PubMed  Google Scholar 

  24. Bergman, R.N., Ider, Y.Z., Bowden, C.R. & Cobelli, C. Quantitative estimation of insulin sensitivity. Am. J. Physiol. 236, E667–E677 (1979).

    CAS  PubMed  Google Scholar 

  25. Ward, W.K., Bolgiano, D.C., McKnight, B., Halter, J.B. & Porte, D. Jr. Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J. Clin. Invest. 74, 1318–1328 (1984).

    Article  CAS  Google Scholar 

  26. Matsuda, M. & DeFronzo, R.A. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22, 1462–1470 (1999).

    Article  CAS  Google Scholar 

  27. Hanson, R.L. et al. Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am. J. Epidemiol. 151, 190–198 (2000).

    Article  CAS  Google Scholar 

  28. Wierup, N., Björkqvist, M., Kuhar, M.J., Mulder, H. & Sundler, F. CART regulates islet hormone secretion and is expressed in the beta-cells of type 2 diabetic rats. Diabetes 55, 305–311 (2006).

    Article  CAS  Google Scholar 

  29. Del Guerra, S. et al. Functional and molecular defects of pancreatic islets in human type 2 diabetes. Diabetes 54, 727–735 (2005).

    Article  CAS  Google Scholar 

  30. Chen, W.M. & Abecasis, G.R. Family-based association tests for genomewide association scans. Am. J. Hum. Genet. 81, 913–926 (2007).

    Article  CAS  Google Scholar 

Download references


The DGI study was supported by a grant from Novartis.

Studies in Malmoe were supported by grants from the Swedish Research Council, including a Linné grant (No. 31475113580), the Diabetes Programme at Lund University, the Påhlsson Foundation, the Heart and Lung Foundation, the Wallenberg Foundation, the Swedish Diabetes Research Society, the Crafoord Foundation, Swedish Medical Society, Swedish Royal Physiographic Society, a Nordic Centre of Excellence Grant in Disease Genetics, the Finnish Diabetes Research Society, the Sigrid Juselius Foundation, Folkhälsan Research Foundation, Novo Nordisk Foundation, the European Network of Genomic and Genetic Epidemiology (ENGAGE), the Wallenberg Foundation, the European Foundation for the Study of Diabetes (EFSD) and the Human Tissue facility at the Lund University Diabetes Center. Studies in human islets were supported in part by the Italian Ministry of University and Research (PRIN 2007-2008) and the European Community (LSHM-CT-2006-518153).

Pancreatic islets at US National Institutes of Health were obtained through the ICR Basic Science Islet Distribution Program (City of Hope Hospital, Joslin Diabetes Center, Northwestern University, Southern California Islet Consortium, University of Alabama Birmingham, University of Illinois, University of Miami, University of Minnesota, University of Pennsylvania, University of Wisconsin and Washington University), the Juvenile Diabetes Research Foundation Islet Resources (Washington University) and the National Disease Resource Interchange (NDRI).

The FUSION study would like to thank the many research volunteers who generously participated in the various studies represented in FUSION. We also thank A.J. Swift, M. Morken, P.S. Chines and N. Narisu for genotying and informatics support. Support for FUSION was provided by the following: NIH grant DK062370 (M. Boehnke), American Diabetes Association research grant 1-05-RA-140 (R.M.W.), DK072193 (K.L. Mohlke) and National Human Genome Research Institute intramural project number 1 Z01 HG000024 (F.S. Collins). The METSIM study was supported by Academy of Finland grant 124243 (M.L.).

Author information

Authors and Affiliations



V.L.: DGI GWAS, data analysis and draft of the report. C.L.F.N., M.R.E.: in vitro expression experiments and analysis, and draft of the report. N.W.: immunocytochemistry. A.J.: genotyping and data analysis. P.S.: in vitro expression experiments. M. Bugliani: microarray and human islets experiments. R.S.: DGI GWAS analysis. M.F.: in vitro physiology. N.P.: genotyping. B.I., T.T.: phenotyping in the Botnia study. P.N.: phenotyping in the Malmoe study. J.K.: data analysis in METSIM study. J.T.: phenotyping in the FUSION study. M. Boehnke: PI of the FUSION study. D.A.: PI of the DGI study. F.S.: immunocytochemistry. J.G.E.: phenotyping in the Helsinki Birth Cohort Study. A.U.J.: FUSION GWAS and data analysis. M.L.: PI of the METSIM study. P.M.: microarray and human islets experiments. R.M.W.: FUSION GWAS analysis. H.M.: design and supervision of in vitro study experiments and draft of the report. L.G. designed and supervised all parts of the study and drafted the report. All researchers took part in the revision of the report and approved the final version.

Corresponding author

Correspondence to Leif Groop.

Supplementary information

Supplementary Text and Figures

Supplementary Figure 1 (PDF 46 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lyssenko, V., Nagorny, C., Erdos, M. et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet 41, 82–88 (2009).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing